Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients

Background: Reliable markers of disease outcomes in multiple sclerosis (MS) would help to predict the response to treatment in patients treated with high efficacy drugs. No evidence of disease activity (NEDA) has become a treatment goal whereas the modified Rio score (MRS) predicts future suboptimal...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Med
Главные авторы: Jamroz-Wiśniewska, Anna, Zajdel, Radosław, Słowik, Agnieszka, Marona, Monika, Wnuk, Marcin, Adamczyk-Sowa, Monika, Adamczyk, Bożena, Lasek-Bal, Anetta, Puz, Przemysław, Stęposz, Arkadiusz, Krzystanek, Ewa, Patalong-Ogiewa, Maja, Pokryszko-Dragan, Anna, Budrewicz, Sławomir, Koziarska, Dorota, Karbicka, Anna, Wawrzyniak, Sławomir, Fryze, Waldemar, Furtak-Niczyporuk, Marzena, Rejdak, Konrad
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI 2021
Предметы:
Brief Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8122749/
https://ncbi.nlm.nih.gov/pubmed/33922368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10091830
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы